Previous education and employments
- 1993 – 1998 daily study Charles University, Prague, Faculty of Pharmacy in Hradec Králové
- 1995 – 1998 – student assistant in the Department of Morphology and Physiology,
- 1998 – 2002 postgraduate study focused on the atherosclerosis, immunohistochemical and stereological methods
- 2003 – 2009 – Assistant in the Department of Morphology and Physiology Faculty of Pharmacy, Hradec Kralove, Charles University, Prague, Czech Republic
- 2009 habilitation in Histology and Embryology, Faculty of Medicine in Hradec Kralove, Charles University in Prague (Docent degree, equiv. Assoc. Prof.). Thesis title: Experimental atherogenesis, quantification and possible affection.
- 2011 Head Chief of the Department of Biological and Medical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University
- 2014 Vice-Dean for Bachelor´s and Follow-Up Master´s Studies and Studies in English, Faculty of Pharmacy in Hradec Kralove, Charles University
- 2017 Full professor in Histology and Embryology, Faculty of Medicine in Hradec Kralove, Charles University.
Research interests
- Experimental atherosclerosis focused on the role of endoglin in atherogenesis both in vivo and in vitro
- Pathology and pharmacology of blood vessels in various pathological conditions
- Histology of placenta, study of transporters and transport proteins
Teaching
- Teacher in the Faculty of Pharmacy
- Human Anatomy, Histology and Physiology
- Pathological Physiology
- Supervisor of diploma thesis 61 students so far
- Supervisor of 11 PhD students (7 already graduated)
- Mentor of 1 post-doctoral fellow
Professional memberships
- Czech Atherosclerosis Society
- Czech Histochemical Society
- European Atherosclerosis Society
Grants received
- Principal investigator 2022-2024 GACR project: Impact of direct endoglin modulation on the development of major complications of metabolic syndrome: atherogenesis and non-alcoholic steatohepatitis.
- Principal investigator 2017-2020 AZV grant project: The relationship of soluble endoglin and hypercholesterolemia in patients with type 2 diabetes mellitus and the impact of therapeutical intervention.
- Principal investigator 2015-2017 GACR project: Tissue and soluble endoglin and their importance in endothelial dysfunction and atherogenesis in vivo and in vitro.
- Senior researcher in Charles University: UNCE project “Centre for investigation of toxic and protective effects of drugs on cardiovascular system” (UNCE 33/2012) 2012-2017.
- Principal investigator 2001 - 2003: grant GA UK „Study of cell adhesion molecules in large and middle sized blood vessels in various pathological situations.”
- Principal investigator - 2002 – 2004: post-doc project GACR „The comparison of the effect of various statins on the expression of cell adhesion molecules in the vessel after induction of hypercholesterolemia”
- from 2000: mentor in 7 GAUK projects for PhD students, co-researcher of other grant projects IGA (1 project), COST project BM0607 (1x)
Awards and prizes
- Travel grants from Czech atherosclerotic society for participating in
- XIV International Symposium on Atherosclerosis, Roma, Italy 2006,
- EAS congress Helsinki, Finland 2007,
- Travel grant from International Atherosclerosis Society for participating in ISA 2009, Boston, USA.
- The first price award for the best original paper (article) published in 2009 from Czech Atherosclerosis Society.
- Nachtigal P., Pospisilova N., Vecerova L., Micuda S., Brcakova E., Pospechova K, Semecky V. Atorvastatin Increases Endoglin, SMAD2, Phosphorylated SMAD2/3 and eNOS Expression in ApoE/LDLR Double Knockout Mice. Journal of Atherosclerosis Thrombosis 2009; 16: 265-74. [IF2010: 2.293]
Summary of all publications
73x original papers in journals with impact factor, 2 original papers in journals without impact factor, 150 abstracts from conferences and symposiums, 73 lectures in conferences and symposiums.
Number publications (in extenso) in WoS: 75
Number of citations in WoS – total 1474, without self-citations 1308
H-index in WoS = 24
2023
Eissazadeh, S., Mohammadi, S., Faradonbeh, F. A., Rathouska, J. U., Nemeckova, I., Tripska, K., Vitverova, B., Dohnalkova, E., Vasinova, M., Fikrova, P., Sa, I. C. I., Micuda, S., and Nachtigal, P. (2023) Endoglin and soluble endoglin in liver sinusoidal endothelial dysfunction in vivo. Biochim Biophys Acta Mol Basis Dis 1870, 166990 [IF= 6.233], AIS 1.213 (Q1)
Barta, P., Nachtigal, P., Maixnerova, J., Zemankova, L., and Trejtnar, F. (2023) Validation of Freshly Isolated Rat Renal Cells as a Tool for Preclinical Assessment of Radiolabeled Receptor-Specific Peptide Uptake in the Kidney. Pharmaceuticals (Basel) 16 [IF= 4.632], AIS 0.770, (Q2)
Igreja Sa, I. C., Tripska, K., Faradonbeh, A, F., Hroch, M., Lastuvkova, H., Schreiberova, J., Kacerovsky, M., Pericacho, M.,Nachtigal, P., and Micuda, S. (2023) Labetalol and soluble endoglin aggravate bile acid retention in mice with ethinylestradiol-induced cholestasis. Front Pharmacol 14, 1116422 [IF= 5.988], AIS 1,059, (Q1)
2022
Tripska, K., Igreja Sa, I. C., Vasinova, M., Vicen, M., Havelek, R., Eissazadeh, S., Svobodova, Z., Vitverova, B., Theuer, C., Bernabeu, C., and Nachtigal, P. (2022) Monoclonal anti-endoglin antibody TRC105 (carotuximab) prevents hypercholesterolemia and hyperglycemia-induced endothelial dysfunction in human aortic endothelial cells. Front Med (Lausanne) 9, 845918 [IF= 5.058], AIS 1,223, (Q2)
2021
Nejmanova, I., Vitverova, B., Eissazadeh, S., Tripska, K., Igreja Sa, I. C., Hyspler, R., Nemeckova, I., Pericacho, M., and Nachtigal, P. (2021) High Soluble Endoglin Levels Affect Aortic Vascular Function during Mice Aging. J Cardiovasc Dev Dis 8 [IF= 3.948], AIS 1,023, (Q2)
Faradonbeh, F. A., Sa, II, Lastuvkova, H., Cermanova, J., Hroch, M., Faistova, H., Mokry, J., Nova, Z., Uher, M., Nachtigal, P., Pavek, P., and Micuda, S. (2021) Metformin impairs bile acid homeostasis in ethinylestradiol-induced cholestasis in mice. Chem Biol Interact 345, 109525 [IF= 3,723], AIS 0,637, (Q2)
Visek, J., Blaha, M., Blaha, V., Lasticova, M., Lanska, M., Andrys, C., Tebbens, J. D., Igreja, E. S. I. C., Tripska, K., Vicen, M., Najmanova, I., and Nachtigal, P. (2021) Monitoring of up to 15 years effects of lipoprotein apheresis on lipids, biomarkers of inflammation, and soluble endoglin in familial hypercholesterolemia patients. Orphanet J Rare Dis 16, 110 [IF= 3.523], AIS 1.217, (Q2)
Ganjali, S., Watts, G. F., Banach, M., Reiner, Z., Nachtigal, P., and Sahebkar, A. (2021) The Yin and Yang of High-density Lipoprotein and Atherosclerotic Cardiovascular Disease: Focusing on Functionality and Cholesterol Efflux to Reframe the HDL Hypothesis. Curr Med Chem [IF= 4,184], AIS 0,743, (Q2)
2020
Vicen, M., Igreja Sa, I. C., Tripska, K., Vitverova, B., Najmanova, I., Eissazadeh, S., Micuda, S., and Nachtigal, P. (2020) Membrane and soluble endoglin role in cardiovascular and metabolic disorders related to metabolic syndrome. Cell Mol Life Sci [IF= 6.496], (Q1), AIS 1,978, (Q1)
Igreja Sa, I. C., Tripska, K., Hroch, M., Hyspler, R., Ticha, A., Lastuvkova, H., Schreiberova, J., Dolezelova, E., Eissazadeh, S., Vitverova, B., Najmanova, I., Vasinova, M., Pericacho, M., Micuda, S., and Nachtigal, P. (2020) Soluble Endoglin as a Potential Biomarker of Nonalcoholic Steatohepatitis (NASH) Development, Participating in Aggravation of NASH-Related Changes in Mouse Liver. Int J Mol Sci 21 [IF= 4.556], (Q1), AIS 0.947, (Q2)
Vitverova, B., Najmanova, I., Vicen, M., Tripska, K., Sa, I. C. I., Hyspler, R., Pericacho, M., and Nachtigal, P. (2020) Long term effects of soluble endoglin and mild hypercholesterolemia in mice hearts. PloS one 15, e0233725 [IF= 2.870], AIS 0.978, (Q2)
Abad, C., Karahoda, R., Kastner, P., Portillo, R., Horackova, H., Kucera, R., Nachtigal, P., and Staud, F. (2020) Profiling of Tryptophan Metabolic Pathways in the Rat Fetoplacental Unit During Gestation. Int J Mol Sci 21. [IF= 4.556], (Q1), AIS 0.947, (Q2)
Markova, I., Konickova, R., Vankova, K., Lenicek, M., Kolar, M., Strnad, H., Hradilova, M., Sachova, J., Rasl, J., Klimova, Z., Vomastek, T., Nemeckova, I., Nachtigal, P., and Vitek, L. (2020) Anti-angiogenic effects of the blue-green alga Arthrospira platensis on pancreatic cancer. J Cell Mol Med [IF= 4.658], (Q1)
2019
Aristorena M, Gallardo-Vara E, Vicen M, de Las Casas-Engel M, Ojeda-Fernandez L, Nieto C, Blanco FJ, Valbuena-Diez AC, Botella LM, Nachtigal P, Corbi AL, Colmenares M, Bernabeu C. MMP-12, Secreted by Pro-Inflammatory Macrophages, Targets Endoglin in Human Macrophages and Endothelial Cells. Int J Mol Sci 2019; 20. [IF= 4,183], AIS 0,932, (Q2)
Dolezelova E, Sa ICI, Prasnicka A, Hroch M, Hyspler R, Ticha A, Lastuvkova H, Cermanova J, Pericacho M, Visek J, Lasticova M, Micuda S, Nachtigal P. High soluble endoglin levels regulate cholesterol homeostasis and bile acids turnover in the liver of transgenic mice. Life Sci 2019:116643. [IF= 3,448], AIS 0,661, (Q2)
Prasnicka A, Lastuvkova H, Alaei Faradonbeh F, Cermanova J, Hroch M, Mokry J, Dolezelova E, Pavek P, Zizalova K, Vitek L, Nachtigal P, Micuda S. Scientific reports 2019; 9:9780. [IF= 4,011], AIS 1,286, (Q1)
Vicen M, Vitverova B, Havelek R, Blazickova K, Machacek M, Rathouska J, Najmanová I, Dolezelova E, Prasnicka A, Sternak M, Bernabeu C, Nachtigal P. Regulation and role of endoglin in cholesterol-induced endothelial and vascular dysfunction in vivo and in vitro. FASEB J 2019:fj201802245R. FASEB. 2018;271:15-25 [IF= 5,595], AIS 1,732, (Q1)
2018
Vitverova B, Blazickova K, Najmanova I, Vicen M, Hyspler R, Dolezelova E, Nemeckova I, Tebbens JD, Bernabeu C, Pericacho M, Nachtigal P. Soluble endoglin and hypercholesterolemia aggravate endothelial and vessel wall dysfunction in mouse aorta. Atherosclerosis. 2018;271:15-25 [IF= 4,239], (Q1)
2017
Prasnicka A, Cermanova J, Hroch M, Dolezelova E, Rozkydalova L, Smutny T, Carazo A, Chladek J, Lenicek M, Nachtigal P, Vitek L, Pavek P, Micuda S. Iron depletion induces hepatic secretion of biliary lipids and glutathione in rats. Biochimica et biophysica acta. 2017;1862:1469-1480 [IF= 4,702]
Varejckova M, Gallardo-Vara E, Vicen M, Vitverova B, Fikrova P, Dolezelova E, Rathouska J, Prasnicka A, Blazickova K, Micuda S, Bernabeu C, Nemeckova I, Nachtigal P. Soluble endoglin modulates the pro-inflammatory mediators nf-kappab and il-6 in cultured human endothelial cells. Life sciences. 2017;175:52-60 [IF= 2,936].
Rathouska J, Fikrova P, Mrkvicova A, Blazickova K, Varejckova M, Dolezelova E, Nemeckova I, Vitverova B, Peslova L, Gallardo-Vara E, Pericacho M, Nachtigal P. High soluble endoglin levels do not induce changes in structural parameters of mouse heart. Heart and vessels. 2017 [IF= 3,434].
Dolezelova E, Stein E, Derosa G, Maffioli P, Nachtigal P, Sahebkar A: Effect of ezetimibe on plasma adipokines: a systematic review and meta-analysis. British journal of clinical pharmacology 2017 [IF= 3,830]
Sahebkar A, Ferri C, Giorgini P, Bo S, Nachtigal P, Grassi D: Effects of pomegranate juice on blood pressure: A systematic review and meta-analysis of randomized controlled trials. Pharmacological research 2017;115:149-161. [IF= 4,408]
2016
Jezkova K, Rathouska J, Nemeckova I, Fikrova P, Dolezelova E, Varejckova M, Vitverova B, Tysonova K, Serwadczak A, Buczek E, Bernabeu C, Lopez-Novoa JM, Chlopicki S, Nachtigal P. High Levels of Soluble Endoglin Induce a Proinflammatory and Oxidative-Stress Phenotype Associated with Preserved NO-Dependent Vasodilatation in Aortas from Mice Fed a High-Fat Diet. J Vasc Res 2016; 53:149-162. [IF= 2,186]
Sahebkar A, Simental-Mendia LE, Pedone C, Ferretti G, Nachtigal P, Bo S, Derosa G, Maffioli P, Watts GF: Statin therapy and plasma free fatty acids: a systematic review and meta-analysis of controlled clinical trials. British journal of clinical pharmacology 2016;81:807-818. [IF= 3,878]
Sahebkar A, Rathouska J, Simental-Mendia LE, Nachtigal P: Statin therapy and plasma cortisol concentrations: A systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacological research 2016;103:17-25. [IF= 4,408] (Q1)
Sahebkar A, Rathouska J, Derosa G, Maffioli P, Nachtigal P: Statin impact on disease activity and C-reactive protein concentrations in systemic lupus erythematosus patients: A systematic review and meta-analysis of controlled trials. Autoimmunity reviews 2016;15:344-353. [IF= 8,490]
Marin V, Rosso N, Dal Ben M, Raseni A, Boschelle M, Degrassi C, Nemeckova I, Nachtigal P, Avellini C, Tiribelli C, Gazzin S: An Animal Model for the Juvenile Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis. PloS one 2016;11:e0158817. [IF= 3,057]
2015
Rathouska J, Jezkova K, Nemeckova I, Nachtigal P. Soluble endoglin, hypercholesterolemia and endothelial dysfunction. Atherosclerosis. 2015;243:383-388 [IF= 3,994]
Kostogrys RB, Johann C, Czyzynska I, Franczyk-Zarow M, Drahun A, Maslak E, Jasztal A, Gajda M, Mateuszuk L, Wrobel TP, Baranska M, Wybranska I, Jezkova K, Nachtigal P, Chlopicki S. Characterisation of atherogenic effects of low carbohydrate, high protein diet (lchp) in apoe/ldlr-/- mice. The journal of nutrition, health & aging. 2015;19:710-718 [IF= 2.996]
Zemankova L, Varejckova M, Dolezalova E, Fikrova P, Jezkova K, Rathouska J, Cerveny L, Botella LM, Bernabeu C, Nemeckova I, Nachtigal P. Atorvastatin-induced endothelial nitric oxide synthase expression in endothelial cells is mediated by endoglin. J Physiol Pharmacol. 2015;66:403-413 [IF= 2.804]
Cermanova J, Kadova Z, Zagorova M, Hroch M, Tomsik P, Nachtigal P, Kudlackova Z, Pavek P, Dubecka M, Ceckova M, Staud F, Laho T, Micuda S. Boldine enhances bile production in rats via osmotic and farnesoid x receptor dependent mechanisms. Toxicol Appl Pharmacol. 2015;285:12-22 [IF= 3.705]
Nemeckova I, Serwadczak A, Oujo B, Jezkova K, Rathouska J, Fikrova P, Varejckova M, Bernabeu C, Lopez-Novoa JM, Chlopicki S, Nachtigal P. High soluble endoglin levels do not induce endothelial dysfunction in mouse aorta. PLoS One. 2015;10:e0119665 [IF= 3.057]
Rathouska J, Jezkova K, Nemeckova I, Zemankova L, Varejckova M, Nachtigal P. Endoglin is not expressed with cell adhesion molecules in aorta during atherogenesis in apoe-deficient mice. Histol Histopathol. 2015;30:233-244 [IF= 2.281]
Rathouska J, Nemeckova I, Zemankova L, Strasky Z, Jezkova K, Varejckova M, Nachtigal P. Cell adhesion molecules and enos expression in aorta of normocholesterolemic mice with different predispositions to atherosclerosis. Heart Vessels. 2015;30:241-248 [IF= 2.126]
2014
Lenicek M, Duricova D, Hradsky O, Dusatkova P, Jiraskova A, Lukas M, Nachtigal P, Vitek L. The relationship between serum bilirubin and crohn's disease. Inflammatory bowel diseases. 2014;20:481-487 [IF= 5.119]
2013
Strasky Z, Zemankova L, Nemeckova I, Rathouska J, Wong RJ, Muchova L, Subhanova I, Vanikova J, Vanova K, Vitek L, Nachtigal P. Spirulina platensis and phycocyanobilin activate atheroprotective heme oxygenase-1: A possible implication for atherogenesis. Food & function. 2013;4:1586-1594 [IF= 2.694]
Ahmadimoghaddam D, Zemankova L, Nachtigal P, Dolezelova E, Neumanova Z, Cerveny L, Ceckova M, Kacerovsky M, Micuda S, Staud F. Organic cation transporter 3 (oct3/slc22a3) and multidrug and toxin extrusion 1 (mate1/slc47a1) transporter in the placenta and fetal tissues: Expression profile and fetus protective role at different stages of gestation. Biol Reprod. 2013;88:55 [IF= 4.027]
2012
Vitek L, Vanikova J, Nachtigal P. Letter by vitek et al regarding article, "niacin inhibits vascular inflammation via the induction of heme oxygenase-1". Circulation. 2012;126:e99 [IF= 15.202]
Vecerova L, Strasky Z, Rathouska J, Slanarova M, Brcakova E, Micuda S, Nachtigal P. Activation of tgf-beta receptors and smad proteins by atorvastatin is related to reduced atherogenesis in apoe/ldlr double knockout mice. J Atheroscler Thromb. 2012;19:115-126 [IF=2.933]
Nachtigal P, Zemankova Vecerova L, Rathouska J, Strasky Z. The role of endoglin in atherosclerosis. Atherosclerosis. 2012;224:4-11 [IF= 3.706]
Ahmadimoghaddam D, Hofman J, Zemankova L, Nachtigal P, Dolezelova E, Cerveny L, Ceckova M, Micuda S, Staud F. Synchronized activity of organic cation transporter 3 (oct3/slc22a3) and multidrug and toxin extrusion 1 (mate1/slc47a1) transporter in transplacental passage of mpp+ in rat. Toxicol Sci. 2012;128:471-481 [IF= 4.328]
2011
Strasky Z, Vecerova L, Rathouska J, Slanarova M, Brcakova E, Kudlackova Z, Andrys C, Micuda S, Nachtigal P. Cholesterol effects on endoglin and its downstream pathways in apoe/ldlr double knockout mice. Circ J. 2011;75:1747-1755 [IF= 3.578]
Stejskalova L, Vecerova L, Perez LM, Vrzal R, Dvorak Z, Nachtigal P, Pavek P. Aryl hydrocarbon receptor and aryl hydrocarbon nuclear translocator expression in human and rat placentas and transcription activity in human trophoblast cultures.Toxicol Sci. 2011;123:26-36 [IF=4.328]
Rathouska J, Vecerova L, Strasky Z, Slanarova M, Brcakova E, Mullerova Z, Andrys C, Micuda S, Nachtigal P. Endoglin as a possible marker of atorvastatin treatment benefit in atherosclerosis. Pharmacol Res. 2011;64:53-59 [IF= 4.346]
Nachtigal P, Sterba M, Popelova O, Vecerova L, Kudlackova Z, Jirkovsky E, Gersl V. Daunorubicin does not induce immunohistochemically detectable endothelial dysfunction in rabbit aorta and femoral artery. Histol Histopathol. 2011;26:551-562 [IF= 2.281]
Kolouchova G, Brcakova E, Hirsova P, Cermanova J, Fuksa L, Mokry J, Nachtigal P, Lastuvkova H, Micuda S. Modification of hepatic iron metabolism induced by pravastatin during obstructive cholestasis in rats. Life Sci. 2011;89:717-724 [IF= 2.555]
2009
Pospechova K, Rozehnal V, Stejskalova L, Vrzal R, Pospisilova N, Jamborova G, May K, Siegmund W, Dvorak Z, Nachtigal P, Semecky V, Pavek P. Expression and activity of vitamin d receptor in the human placenta and in choriocarcinoma bewo and jeg-3 cell lines. Mol Cell Endocrinol. 2009;299:178-187 [IF= 4.039]
Popelova O, Sterba M, Haskova P, Simunek T, Hroch M, Guncova I, Nachtigal P, Adamcova M, Gersl V, Mazurova Y. Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: Effective rescue of cardiomyocytes from apoptotic cell death. Br J Cancer. 2009;101:792-802 [IF= 5.082]
Nachtigal P, Vecerova L, Pospisilova N, Micuda S, Brcakova E, Navarro Hernandez E, Pospechova K, Semecky V. Endoglin co-expression with enos, smad2 and phosphorylated smad2/3 in normocholesterolemic and hypercholesterolemic mice: An immunohistochemical study. Histol Histopathol. 2009;24:1499-1506 [IF=2.281]
Nachtigal P, Pospisilova N, Vecerova L, Micuda S, Brcakova E, Pospechova K, Semecky V. Atorvastatin increases endoglin, smad2, phosphorylated smad2/3 and enos expression in apoe/ldlr double knockout mice. J Atheroscler Thromb. 2009;16:265-274 [IF=2.933]
Mladenka P, Zatloukalova L, Simunek T, Bobrovova Z, Semecky V, Nachtigal P, Haskova P, Mackova E, Vavrova J, Holeckova M, Palicka V, Hrdina R. Direct administration of rutin does not protect against catecholamine cardiotoxicity. Toxicology. 2009;255:25-32 [IF= 4.017]
Mladenka P, Semecky V, Bobrovova Z, Nachtigal P, Vavrova J, Holeckova M, Palicka V, Mazurova Y, Hrdina R. The effects of lactoferrin in a rat model of catecholamine cardiotoxicity. Biometals. 2009;22:353-361 [IF= 3.284]
Mladenka P, Kalinowski DS, Haskova P, Bobrovova Z, Hrdina R, Simunek T, Nachtigal P, Semecky V, Vavrova J, Holeckova M, Palicka V, Mazurova Y, Jansson PJ, Richardson DR. The novel iron chelator, 2-pyridylcarboxaldehyde 2-thiophenecarboxyl hydrazone, reduces catecholamine-mediated myocardial toxicity. Chem Res Toxicol. 2009;22:208-217 [IF= 3.667]
Mladenka P, Hrdina R, Bobrovova Z, Semecky V, Vavrova J, Holeckova M, Palicka V, Mazurova Y, Nachtigal P. Cardiac biomarkers in a model of acute catecholamine cardiotoxicity. Hum Exp Toxicol. 2009;28:631-640 [IF= 1.453]
2008
Sadlonova J, Kostal M, Smahelova A, Hendl J, Starkova J, Nachtigal P. Selected metabolic parameters and the risk for uterine fibroids. Int J Gynaecol Obstet. 2008;102:50-54 [IF=0.546]
Nachtigal P, Pospisilova N, Jamborova G, Pospechova K, Solichova D, Andrys C, Zdansky P, Micuda S, Semecky V. Atorvastatin has hypolipidemic and anti-inflammatory effects in apoe/ldl receptor-double-knockout mice. Life Sci. 2008;82:708-717 [IF=2.555]
Jamborova G, Pospisilova N, Semecky V, Hyspler R, Ticha A, Pospechova K, Solichova D, Maxova M, Briestensky J, Real KJ, Nachtigal P. Microdispersed oxidized cellulose as a novel potential substance with hypolipidemic properties. Nutrition. 2008;24:1174-1181 [IF= 2.859]
2007
Syka J, Ouda L, Nachtigal P, Solichova D, Semecky V. Atorvastatin slows down the deterioration of inner ear function with age in mice. Neurosci Lett. 2007;411:112-116 [IF= 2.026]
Pospechova K, Kopecky M, Nachtigal P, Pospisilova N, Jamborova G, Semecky V. Changes in the expression of p-cadherin in the normal, cryptorchid and busulphan-treated rat testis. Int J Androl. 2007;30:430-438 [IF= 3.565]
Pavek P, Cerveny L, Svecova L, Brysch M, Libra A, Vrzal R, Nachtigal P, Staud F, Ulrichova J, Fendrich Z, Dvorak Z. Examination of glucocorticoid receptor alpha-mediated transcriptional regulation of p-glycoprotein, cyp3a4, and cyp2c9 genes in placental trophoblast cell lines. Placenta. 2007;28:1004-1011 [IF= 3.117]
Nachtigal P, Pospisilova N, Jamborova G, Pospechova K, Solichova D, Andrys C, Zdansky P, Semecky V. Endothelial expression of endoglin in normocholesterolemic and hypercholesterolemic c57bl/6j mice before and after atorvastatin treatment.Can J Physiol Pharmacol. 2007;85:767-773 [IF= 1.556]
2006
Staud F, Vackova Z, Pospechova K, Pavek P, Ceckova M, Libra A, Cygalova L, Nachtigal P, Fendrich Z. Expression and transport activity of breast cancer resistance protein (bcrp/abcg2) in dually perfused rat placenta and hrp-1 cell line. J Pharmacol Exp Ther. 2006;319:53-62 [IF= 3.891]
Pospisilova N, Semecky V, Jamborova G, Pospechova K, Solichova D, Andrys C, Zdansky P, Nachtigal P. Endoglin expression in hyper-cholesterolemia and after atorvastatin treatment in apoe-deficient mice. J Pharm Pharm Sci. 2006;9:388-397 [IF= 2.198]
Nachtigal P, Pospisilova N, Pospechova K, Jamborova G, Kopecky M, Jaynes R, Briestensky J, Santar I, Smahelova A, Solichova D, Zdansky P, Semecky V. Mdoc and atorvastatin have potential antiinflammatory effects in vascular endothelium of apoe-/- mouse model of atherosclerosis. Life Sci. 2006;78:1983-1989 [IF=2.555]
Nachtigal P, Jamborova G, Pospisilova N, Pospechova K, Solichova D, Zdansky P, Semecky V. Atorvastatin has distinct effects on endothelial markers in different mouse models of atherosclerosis. J Pharm Pharm Sci. 2006;9:222-230 [IF=2.198]
Ceckova M, Libra A, Pavek P, Nachtigal P, Brabec M, Fuchs R, Staud F. Expression and functional activity of breast cancer resistance protein (bcrp, abcg2) transporter in the human choriocarcinoma cell line bewo. Clin Exp Pharmacol Physiol. 2006;33:58-65 [IF= 2.160]
2005
Nachtigal P, Kopecky M, Solichova D, Zdansky P, Semecky V. The changes in the endothelial expression of cell adhesion molecules and inos in the vessel wall after the short-term administration of simvastatin in rabbit model of atherosclerosis. J Pharm Pharmacol. 2005;57:197-203 [IF= 2.033]
Kopecky M, Semecky V, Nachtigal P. Vimentin expression during altered spermatogenesis in rats. Acta Histochem. 2005;107:279-289 [IF= 1.608]
2004
Nachtigal P, Semecky V, Kopecky M, Gojova A, Solichova D, Zdansky P, Zadak Z. Application of stereological methods for the quantification of vcam-1 and icam-1 expression in early stages of rabbit atherogenesis. Pathol Res Pract. 2004;200:219-229 [IF= 1.213]
Kopecky M, Semecky V, Trejtnar F, Laznicek M, Laznickova A, Nachtigal P, Decristoforo C, Mather SJ, Macke HR. Analysis of accumulation of 99mtc-octreotide and 99mtc-edda/hynic-tyr3-octreotide in the rat kidneys. Nucl Med Biol. 2004;31:231-239 [IF=2.517]
2002
Nachtigal P, Semecky V, Gojova A, Kopecky M, Benes V, Juzkova R: The application of stereological methods for the quantitative analysis of the atherosclerotic lesions in rabbits. Image Analysis and Stereology, 2002;21:165-174
2001
Nachtigal P, Gojova A, Semecky V. The role of epithelial and vascular-endothelial cadherin in the differentiation and maintenance of tissue integrity. Acta Medica (Hradec Kralove). 2001;44:83-87